FindTrial
Sign In

Effect of anti diarrhoeal medicine, loperamide, in Autism

Effectiveness of Loperamide on social interaction and communication in Autism spectrum disorder- a randomised open label multistage trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/04/051921
Enrollment
30
Registered
2023-04-24
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F840- Autistic disorder

Interventions

Intervention1: treatment with Loperamide: tab. loperamide 0.25mg for 2weeks and then 0.5mg for next 2weeks in patients with Autism spectrum disorder Control Intervention1: Treatment as usual: Treatmen

Sponsors

Central Institute of Psychiatry
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Children receiving a diagnosis of Autism Spectrum Disorder as per DSM 5 2. Children of either sex aged 4 to 10 years of age 3. Guardian(s) giving written informed consent.

Exclusion criteria

Exclusion criteria: Children with ASD having intellectual disability, significant sensory and motor impairment, known genetic disorders, seizures at the time of enrolment or other neurological disorders, significant medical or neurological illness (endocrinopathies) or pre-existing constipation.

Design outcomes

Primary

MeasureTime frame
Effectiveness of Loperamide on social interaction and communication in patients of Autism Spectrum Disorder on SRS2 scale Timepoint: baseline, 2weeks, 4weeks—

Secondary

MeasureTime frame
serum Enkephalin levelsTimepoint: baseline, 4weeks—

Countries

India

Contacts

Public ContactDr Varun S Mehta

Central Institute of Psychiatry

vs_mehta@yahoo.co.in9204858189

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026